Sling Therapeutics reports 82% sustained response with linsitinib in thyroid eye disease
Sling reports 82% sustained response among linsitinib responders after 48 weeks off therapy. See why Phase 3 ORBIT is the next critical test.
Pharma & Biotech
Features & Analysis
Dr. Raymond Douglas weighs Amgen’s Tepezza as Viridian’s Lumvoa widens TED choices
Amgen’s Tepezza is facing a broader thyroid eye disease treatment landscape after Viridian Therapeutics’ Lumvoa became another approved option, shifting attention toward how physicians may weigh evidence, safety, treatment burden and patient fit. Dr. Raymond Douglas, MD, PhD, who served as principal investigator in the international Tepezza trials that supported its United States Food and
Pharma & Biotech
FDA approves Lumvoa for thyroid eye disease as Viridian enters commercial biotech
See how Lumvoa’s FDA approval could reshape thyroid eye disease treatment, challenge Tepezza and test Viridian’s launch strategy.
Pharma & Biotech
Can Minghui Pharmaceutical’s MHB018A challenge established thyroid eye disease therapies?
Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.
Pharma & Biotech
Viridian Therapeutics financing puts thyroid eye disease expansion strategy in sharper focus
Viridian has TED trial wins, but market entry needs capital. See why its $350m raise matters before commercialization.